Form 4: ResMed CFO Brett Sandercock Reports Stock Sale Under 10b5-1 Plan
SEC Form 4 Filing
ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed common stock at $249 per share under a pre-arranged 10b5-1 trading plan.
Summary
- On November 8, 2024, Brett Sandercock, the Chief Financial Officer of ResMed Inc., sold 1,000 shares of ResMed common stock.
- The sale was executed at a price of $249 per share.
- The transaction was conducted under a Rule 10b5-1 plan adopted on February 6, 2024.
- Following the transaction, Sandercock beneficially owns 94,864 shares of ResMed stock, which includes 51.807 shares purchased through the ResMed Employee Stock Purchase Plan on October 31, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock sale by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The stock sale by a high-ranking officer may cause minor short-term concern among shareholders, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| February 6, 2024 | Date the Rule 10b5-1 plan was adopted. |
| October 31, 2024 | Date of ResMed Employee Stock Purchase Plan. |
| November 8, 2024 | Date of the stock sale transaction. |
| November 12, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.